Researchers find promise for ctDNA-guided immunotherapy for patients with MIBC who underwent radical cystectomy.
Urothelial Carcinoma Diagnostics
Advertisement
John P. Sfakianos, MD, discusses the history and use of ctDNA in the GU oncology field.
Dr. Koshkin highlights emerging data on Nectin-4–targeted imaging and radiopharmaceuticals in urothelial cancer.
Dr. Koshkin shares an overview of FAP-targeted theranostics, including UCSF-led studies showing FAP PET imaging’s ability.
Previous research has shown that BLC can provide improved detection rates, mainly for high-risk disease and invasive tumors.
This newly developed assay can assess the genomic profile of ctDNA in patients with advanced UC.
Dr. Lotan discusses risk stratification and outlines the next steps for integrating Cxbladder Triage into clinical practice.
Dr. Lotan describes the design and key findings of the STRATA trial using Cxbladder Triage for patients with microhematuria.
Dr. Jensen highlights the single-arm trial design and TOMBOLA's use of ctDNA.
ctDNA testing may help identify patients with bladder cancer who would benefit from early post-cystectomy immunotherapy.
Drs. Gupta and Kohlmann focus on the prevalence of pathogenic variants in the urethra, upper tract, and bladder.
Video Insights
Conference Coverage
At 12 months, the OS rate for patients who received treatment with ipilimumab plus nivolumab was superior to SOC.
The Two Onc Docs review QOL related to doublet ADT with darolutamide, niraparib with abiraterone for mCSPC, and more.
The Two Onc Docs review the 5-year follow-up data on adjuvant pembro and a final analysis on ipi/nivo for metastatic disease.
The Two Onc Docs weigh IO for BCG-refractory NMIBC, ctDNA monitoring for patients receiving gem/cis for MIBC, and more.
Dr. Machaalani highlights his study that evaluated the association between circulating KIM-1 and mRCC tumor biology.
Dr. James showcases an MMAI model to identify benefit from 2nd-generation ARPIs in hr/nm PCa patients from STAMPEDE.
Advertisement
Advertisement
Trending
The study’s major efficacy outcomes included a complete response in 78% of patients.
The Two Onc Docs weigh IO for BCG-refractory NMIBC, ctDNA monitoring for patients receiving gem/cis for MIBC, and more.
Drs. Necchi and Tawagi break down in detail the first results of SURE-02 in patients with muscle-invasive bladder cancer.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.